Chardan Capital Maintains Buy on Krystal Biotech, Raises Price Target to $153
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits maintains a 'Buy' rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $148 to $153.
August 08, 2023 | 8:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital maintains a 'Buy' rating on Krystal Biotech and raises the price target from $148 to $153, which could positively impact the stock's price.
The 'Buy' rating maintained by Chardan Capital indicates a positive outlook for Krystal Biotech. The increase in price target from $148 to $153 suggests that the analyst sees potential for the stock's price to rise, which could lead to a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100